Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
HLH Biopharma
- Ownership
- Private
- Development stage
- Other
01
Overview
HLH Biopharma is a biotechnology company dedicated to developing targeted therapies for Hemophagocytic Lymphohistiocytosis (HLH) and related hyperinflammatory conditions. The company's primary focus is on the development of HLH-101, a selective Janus kinase 1 (JAK1) inhibitor designed to manage the life-threatening cytokine storms associated with primary and secondary HLH. By targeting the JAK/STAT signaling pathway, HLH Biopharma aims to provide more precise and less toxic treatment options compared to current standard-of-care chemotherapy and immunosuppression. The company is currently advancing its lead candidate through pre-clinical studies to support future clinical applications in pediatric and adult populations.
- Therapeutic areas
- HematologyImmunologyRheumatology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on HLH Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLH Biopharma.